Finanzen von First Tracks Biotherapeutics Inc (TRAX)TRAXFirst Tracks Biotherapeutics Inc

In the context of the broader market, TRAX competes directly with industry leaders such as ABSI and TYRA. With a market capitalization of $1.57B, it holds a leading position in the sector. When comparing efficiency, TRAX's gross margin of N/A stands against ABSI's 100.00% and TYRA's N/A. Such benchmarking helps identify whether First Tracks Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a net income loss of $33.37 million in Q2 2026, with a current ratio of 14.28 indicating strong liquidity. The forward P/E ratio is currently at 0, suggesting no earnings expectations in the near term, which is typical for biotech firms in development stages.